C4 Therapeutics, Inc. (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company developing targeted protein degradation (TPD) medicines, most notably its lead oral degrader cemsidomide for multiple myeloma. With the shares trading near $3.10 in early November 2026, investors are asking whether the stock can climb to a $13 level that sits far above the current quote. The short answer is that this is a plausible, widely discussed scenario—but one tied almost entirely to clinical data rather than current financials.
Because C4 Therapeutics is pre-profit and its value is tied to pipeline milestones, analyst price targets vary enormously. Reviewing eight current, attributed targets yields a range from $7 to $30. On the cautious end, CCCC carries $7 targets from Barclays (Etzer Darout, February 2026) and Guggenheim (Brad Canino, October 2026). Mid-range targets include $10 from J.P. Morgan (Anupam Rama, October 2026) and Wells Fargo (Derek Archila, August 2026), $11 from Lake Street (October 2026), and $12 from Evercore ISI (Gavin Clark-Gartner, June 2026). Jefferies (Biren Amin) holds a $14 target, while Brookline Capital (Leah Rush) is the outlier at $30, raised in February 2026 on confidence in the Phase 2 MOMENTUM trial.
The arithmetic mean of these eight targets is about $12.63, which rounds to the $13 central target used in this article. Note that this is an average of individual analyst forecasts, not an official published consensus, and the $7-to-$30 spread underscores how much disagreement exists about the company's ultimate value.
With the stock near $3.10, moving to $13 implies an upside of roughly 320%, a very large move. The 52-week range of roughly $1.69 to $5.17 shows how volatile the shares have been. C4 Therapeutics reported revenue of about $6.6 million and a GAAP net loss of about $23.6 million for the June 2026 quarter, and it holds roughly $300 million in cash, which management has indicated provides a runway into late 2028. Because there is no meaningful earnings base to value today, the path to $13 depends on clinical data de-risking the pipeline and expanding the perceived addressable market for cemsidomide.
Several verified factors underpin the constructive analyst view. Cemsidomide, an orally bioavailable degrader targeting IKZF1/3, is advancing in multiple myeloma, including the Phase 2 MOMENTUM trial and a Phase 1b combination study with Pfizer's elranatamab (Elrexfio) under a collaboration announced in late 2025. A $125 million underwritten offering completed in October 2025 strengthened the balance sheet and attracted participation from specialist life-science investors. Analysts have repeatedly cited cemsidomide's differentiated safety and tolerability profile, and the consensus rating remains uniformly positive, with no Sell or Hold ratings among recent coverage.
The principal risk is clinical: if cemsidomide or other pipeline assets such as CFT8919 fail to show compelling efficacy or safety, the valuation case behind the higher targets collapses. The company is loss-making, revenue is modest and forecast to decline in the near term, and further capital raises could dilute existing shareholders. The unusually wide analyst range—from $7 to $30—reflects the reality that a single negative readout could sharply reset expectations, while the stock has also shown a tendency to retrace sharply after strong rallies.
From a technical standpoint, the shares are trading in the lower portion of their 52-week range of approximately $1.69 to $5.17. The $5 area represents a notable resistance level, as it aligns with prior highs, and a sustained move through it would be required before the stock could even begin to contemplate the $13 zone. On the downside, support has formed near the $2-to-$3 area where the stock has repeatedly found buyers over the past year. The $13 target itself is a psychological and technical milestone far above the stock's current long-term structure.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may use different assumptions. For CCCC, the key catalysts are clinical, not quarterly. Investors should monitor cemsidomide data from the MOMENTUM trial and the Phase 1b elranatamab combination study, any updates on CFT8919, the company's cash position and financing activity, and any analyst target revisions that follow data readouts. Quarterly earnings and guidance remain secondary to the clinical calendar.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive name like C4 Therapeutics, these signals can help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual review. Explore the AI Daily Buy/Sell Signals page to see how automated tools can complement your own research.
The $13 central target—an average of eight analyst targets rounded from $12.63—represents a roughly 320% move from the recent price near $3.10, a very large gain that is entirely contingent on clinical success. The strongest supports are cemsidomide's profile, the Pfizer collaboration, a fortified cash position, and a uniformly positive analyst consensus. The principal obstacles are binary clinical risk, near-term revenue weakness, and dilution. With targets ranging from $7 to $30, analysts themselves disagree sharply on the outcome. Whether CCCC can reach $13 will ultimately be decided by data, not by the current price or sentiment, and there is no guarantee it will do so.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CCCC has been loosely correlated with NTLA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CCCC jumps, then NTLA could also see price increases.
| Ticker / NAME | Correlation To CCCC | 1D Price Change % | ||
|---|---|---|---|---|
| CCCC | 100% | -4.76% | ||
| NTLA - CCCC | 44% Loosely correlated | -7.76% | ||
| RCKT - CCCC | 43% Loosely correlated | -3.16% | ||
| SVRA - CCCC | 43% Loosely correlated | -2.57% | ||
| SLDB - CCCC | 42% Loosely correlated | +2.14% | ||
| FDMT - CCCC | 42% Loosely correlated | -0.16% | ||
More | ||||